Novo Nordisk said on Wednesday it will launch some doses of its oral semaglutide for diabetes under the brand name Ozempic pill in the second quarter of this year. ...

Novo Nordisk is increasingly looking like the loser in the battle for market share in weight-loss drugs: Here's your Evening Briefing https://t.co/vjko3l3FzG ...

Market Overview - The U.S. stock market is experiencing mixed trading patterns with a notable rotation out of technology giants and into broader market sectors [1] - The S&P 500 has slipped around 0.2% to 0.3%, marking a modest decline for the fourth time in the last five days [2] - The Nasdaq Composite has traded approximately 1% lower, with the Nasdaq 100 specifically seeing a 1.4% loss [2] - The Dow Jones Industrial Average has risen by as much as 389 points, or 0.8%, indicating a shift away from tech stocks towards firms expected to benefit from improving growth prospects [2] Economic Indicators - The yield on 10-year Treasuries has remained steady at 4.28% [3] - Upcoming economic data includes the ADP Employment Change and ISM Services PMI for January, which are crucial for assessing the labor market and services sector [5] - The week will culminate with the U.S. Employment Report on February 6th, which includes non-farm payrolls and average hourly earnings [6] Company-Specific Highlights - Advanced Micro Devices (AMD) shares dropped by as much as 15.7% despite stronger-than-expected profits, indicating high expectations for AI-related companies [9] - Uber Technologies (UBER) fell 3% to 5% after its quarterly results and profit forecast fell short of expectations [10] - Super Micro Computer (SMCI) rallied by 12% to 14% after delivering stronger-than-expected profits [10] - Eli Lilly (LLY) surged by 9.2% after exceeding profit expectations and providing strong guidance, driven by its obesity drugs [11] - Silicon Laboratories (SLAB) shares soared by 51% following the announcement of its acquisition by Texas Instruments for approximately $7.5 billion [13] - Nvidia (NVDA) shares declined 2.8% due to a broad tech sell-off and uncertainty surrounding its OpenAI investment [14]

Core Viewpoint - Bernstein maintains a "Market Perform" rating for Merck, adjusting the price target from $95 to $100, indicating cautious optimism about the company's future performance [1][6] Financial Performance - Merck's fourth-quarter 2025 results show adjusted earnings per share (EPS) of $2.04, slightly above the Zacks Consensus Estimate of $2.03, representing a 19% increase year-over-year [2] - The company's revenues for the quarter reached $16.4 billion, reflecting a 5% year-over-year growth and surpassing the Zacks Consensus Estimate of $16.19 billion [2] Key Product Contribution - Keytruda, Merck's flagship product, generated $8.37 billion in sales during the quarter, marking a 5% increase [3] 2026 Outlook - Merck's 2026 revenue projection is between $65.5 billion and $67 billion, below analysts' estimates of $67.6 billion [4] - The company expects adjusted EPS between $5 and $5.15, compared to the anticipated $5.36, which includes a $9 billion one-time charge related to the acquisition of Cidara Therapeutics [4] Strategic Response - To address challenges, Merck plans to reduce costs by $3 billion by 2027 and continue investing in its pipeline and acquisitions, aiming to mitigate the effects of future patent expirations [5] - Despite challenges, Merck's market capitalization remains robust at approximately $289.39 billion, with a trading volume of 25.57 million shares [5]

Market Overview - The US market is experiencing a divergence, with the Dow gaining over 80 points (almost 0.2%), while the S&P 500 is down about 0.33% and the Nasdaq down 0.9% due to a sell-off in software stocks [3][8]. - Bitcoin remains below the critical level of $75,000, which is seen as an important technical level for future price movements [4][9]. Software and Technology Sector - The software sector is facing significant declines, with most stocks in the sector showing deep red, indicating ongoing selling pressure without specific catalysts [6][7]. - Concerns about AI potentially supplanting the functionality of existing software products are contributing to the malaise in the sector [7][9]. - Major tech companies like Apple, Nvidia, and Meta are also experiencing declines, with Nvidia down 2% and Meta down 3% [8][9]. Uber's Performance - Uber reported strong quarterly results with bookings up 22%, revenue up 20%, and EBITDA up 35%, but the guidance was in line with expectations rather than exceeding them [11][12]. - The company faces long-term risks from the potential disruption caused by autonomous vehicles (AVs), which could impact its market share and overall take rate [12][13]. Upcoming Earnings Reports - Alphabet and Amazon are set to report earnings soon, with Alphabet expected to show strong performance in its search and cloud businesses, potentially growing over 40% [21][22]. - Amazon is anticipated to perform well due to its interconnected businesses in retail, advertising, and AWS, with expectations of over 30% stock performance growth [25][26]. Pfizer's Strategy in Obesity Drugs - Pfizer is entering the competitive weight loss drug market, with a focus on developing a differentiated portfolio of injectables and oral medications [64][66]. - The company aims to address unmet medical needs in the obesity market, which is expected to grow significantly despite existing competition [67][70]. Analyst Calls and Market Reactions - Super Micro's price target was lowered due to margin pressures, while Chipotle's target was also cut following a same-store sales decline [47][48]. - Five Below received an upgrade due to new leadership and a strategic focus shift, while Boston Scientific's shares fell after issuing a soft forecast for 2026 [49][60].

Market Overview - Pre-market futures have shown a recovery from early lows, influenced by Q4 earnings reports and private-sector job numbers, with the Dow up by 142 points and the S&P 500 up by 10 points, while the Nasdaq is down by 66 points [1] Employment Data - Private-sector payrolls for January reported by ADP came in at +22K, significantly below expectations, and down from a revised +37K the previous month, marking the first back-to-back monthly job gains since April and May of the previous year [2] - Services employment accounted for most of the private-sector hires, with +21K in services compared to only +1K in goods-producing sectors; Healthcare Services led with +74K hires, followed by Financial Services with +14K and Construction with +9K, while Professional & Business Services lost -57K jobs [3] - ADP Chief Economist noted that hiring trends are following consumer demand rather than technology advancements, indicating a disconnect between stock market performance and private-sector job growth [4] Sector Insights - The job gains in the Construction sector may hint at increased labor demand due to data-center buildouts, although it is considered premature to draw definitive conclusions [5] - A new ADP methodology revealed a downward adjustment of -212K fewer hires for the private sector in 2025, reducing total expected hires from +771K in 2024 to +398K in 2025, which may provide a clearer picture of the labor market [6] Earnings Reports - Eli Lilly & Co. reported a +7.9% earnings surprise with earnings of $7.54 per share and revenues of $19.29 billion, driven by strong performance in diabetes and weight loss drugs [8] - AbbVie reported earnings of $2.71 per share, exceeding estimates of $2.66, while Novartis reported $2.03 per share, beating consensus by 4 cents; however, AbbVie shares fell by -3% despite the positive earnings [9] - Phillips 66 reported earnings of $2.47 per share, surpassing expectations of $2.11 and significantly improving from a loss of -$0.15 per share in the same quarter last year, with shares up by +1.3% in pre-market trading [10]

Core Insights - AbbVie reported revenue of $16.62 billion for the quarter ended December 2025, reflecting a 10% increase year-over-year and a surprise of +1.58% over the Zacks Consensus Estimate of $16.36 billion [1] - The earnings per share (EPS) for the quarter was $2.71, up from $2.16 in the same quarter last year, with an EPS surprise of +2.02% compared to the consensus estimate of $2.66 [1] Revenue Performance by Product - Humira's net revenue in the US was $897 million, significantly below the average estimate of $574.85 million, representing a year-over-year decline of -28% [4] - Internationally, Humira generated $349 million, slightly below the estimated $374.4 million, marking a -20% change year-over-year [4] - Oncology product Elahere reported $182 million, which was below the average estimate of $191.62 million but showed a +23% increase year-over-year [4] - Qulipta's international revenue reached $43 million, exceeding the estimate of $39.74 million, with a remarkable +186.7% year-over-year growth [4] - The Juvederm Collection generated $249 million, below the estimate of $272.17 million, reflecting a -10.8% year-over-year decline [4] - Vraylar's total revenue was $1.02 billion, surpassing the estimate of $994.67 million, with a +10.6% year-over-year increase [4] - Imbruvica's revenue was $671 million, below the average estimate of $714.9 million, showing a -20.9% year-over-year decline [4] - Eye Care products generated $580 million, slightly above the estimate of $568.88 million, with a -10.2% year-over-year change [4] - Botox Therapeutic revenue was $990 million, close to the estimate of $995.91 million, reflecting a +13.4% year-over-year increase [4] - Aesthetics revenue totaled $1.29 billion, slightly above the estimate of $1.28 billion, with a -0.9% year-over-year change [4] - Venclexta generated $710 million, below the estimate of $725.34 million, with an +8.4% year-over-year increase [4] - Neuroscience product Vyalev reported $183 million, exceeding the estimate of $170.15 million [4] Stock Performance - AbbVie shares returned +0.8% over the past month, compared to a +0.9% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Viewpoint - The article discusses the competitive landscape between Eli Lilly and Novo Nordisk, highlighting their positions within the pharmaceutical industry and the potential for investment opportunities in these companies [1]. Group 1: Company Analysis - Eli Lilly (LLY) and Novo Nordisk (NVO) are compared as archrivals in the pharmaceutical sector, with a focus on their market strategies and financial performance [1]. - The analysis aims to identify potential high-return investments, specifically targeting small- and mid-cap companies in the life sciences sector [1]. Group 2: Investment Focus - The author emphasizes a fundamental analysis approach to uncover potential "5–10 baggers," indicating a focus on companies that could significantly increase in value [1]. - The investment strategy includes a focus on early-commercial-stage life sciences companies, insurers, homebuilders, and select consumer-facing businesses [1].

Core Insights - Emcure Pharmaceuticals is leveraging social media influencers and celebrities to promote its semaglutide brand, Poviztra, aiming to establish a strong presence in the weight-loss market [1][2][4] - The marketing strategy for GLP-1 drugs is evolving, moving beyond traditional doctor-focused approaches to include broader consumer engagement, similar to trends seen in Western markets [2][10] Company Strategy - Emcure launched Poviztra in December 2023 in partnership with Novo Nordisk, and is implementing a campaign called "Winning Over Obesity" featuring celebrities and influencer-doctors to raise awareness about obesity [1][4] - The company is focusing on educating both consumers and healthcare professionals about the benefits and safety of semaglutide, addressing misinformation prevalent on social media [5][6] Market Position - Poviztra is positioned as a competitive offering in the Indian market, with a pricing structure starting at approximately ₹2,200 per week, or ₹8,790 per month, across various strengths [7] - As the generic market for semaglutide opens next month, Emcure is expected to maintain competitive pricing while expanding awareness and access to its product [8] Financial Performance - Emcure reported a profit after tax of ₹231 crore in Q3FY26, reflecting a 48.2% year-on-year increase, with revenue rising 20.4% to ₹2,363 crore, driven by strong domestic and international performance [13][14] - The domestic business grew by 15.4%, particularly in chronic therapy segments, while international operations saw a 24.5% growth, indicating robust demand across all markets [14]

Core Insights - Eli Lilly and Company (LLY) reported strong fourth-quarter 2025 results, with adjusted earnings per share (EPS) of $7.54, exceeding the Zacks Consensus Estimate of $6.99, and a year-over-year earnings increase of 42% [1] - Revenues reached $19.3 billion, a 43% increase year over year, driven by the success of GLP-1 drugs Mounjaro and Zepbound, surpassing the Zacks Consensus Estimate of $17.87 billion [1] Revenue Drivers - Mounjaro generated sales of $7.41 billion, up 110% year over year, exceeding the Zacks Consensus Estimate of $6.65 billion [2] - Zepbound recorded sales of $4.26 billion, a 123% increase year over year, also beating the Zacks Consensus Estimate of $3.87 billion [3] Competitive Landscape - Mounjaro and Zepbound face competition from Novo Nordisk's semaglutide products, with Novo Nordisk reporting a decline in its Diabetes and Obesity Care segment sales due to competitive pressure from Lilly's offerings [4] - Despite competitive dynamics, Mounjaro and Zepbound are expected to maintain strong demand in 2026 [13] Other Drug Performance - Trulicity generated $1.04 billion in revenue, down 17% year over year, but still beating the Zacks Consensus Estimate of $1.0 billion [5] - Jardiance sales fell 36% to $768 million, missing the Zacks Consensus Estimate of $776 million [5] - Taltz brought in $1.05 billion, up 10% year over year, exceeding the Zacks Consensus Estimate of $955 million [6] - Verzenio generated $1.60 billion, up 3% year over year, but missed the Zacks Consensus Estimate of $1.62 billion [6] Full-Year Performance - For the full year 2025, Eli Lilly's sales rose 45% to $65.2 billion, significantly beating the Zacks Consensus Estimate of $63.54 billion [10] - Adjusted earnings for 2025 were $24.21 per share, an 86% increase year over year, surpassing the Zacks Consensus Estimate of $23.74 [10] 2026 Outlook - Eli Lilly expects 2026 revenues in the range of $80 billion to $83 billion, higher than the Zacks Consensus Estimate of $77.5 billion [11] - EPS for 2026 is projected to be between $33.50 and $35.00, exceeding the Zacks Consensus Estimate of $33.24 [11] Market Reaction - Following the positive quarterly earnings and optimistic 2026 outlook, Lilly's shares rose approximately 9% in pre-market trading [14] - Over the past year, Lilly's stock has increased by 19.2%, outperforming the industry average of 17.1% [14] Strategic Initiatives - Lilly is investing in obesity treatments and has several new molecules in clinical development, including orforglipron, an oral GLP-1 small molecule [16][17] - The company is diversifying its portfolio beyond GLP-1 drugs into cardiovascular, oncology, and neuroscience areas, including recent acquisitions to enhance its capabilities in oral small-molecule therapies [19]